menu
    • menu

    Company profile for Ajax Therapeutics

    NEW Drugs in Dev: 2
    Coral

    Virtual Booth

    Contact Supplier

    China’s top API & intermediate manufacturer, delivering advanced CMO/CDMO solutions to 60+ countries, empowering global health progress

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Advances in molecular genetics and biology have led to the development of new classes of targeted therapies for the treatment of hematologic malignancies. However, many of these therapies, while selective for a particular drug target, often interact with other related proteins which can limit their efficacy and lead to unwanted side effects. At Ajax, we are targeting hematologic malignancies with greater precision by applyin...
    Advances in molecular genetics and biology have led to the development of new classes of targeted therapies for the treatment of hematologic malignancies. However, many of these therapies, while selective for a particular drug target, often interact with other related proteins which can limit their efficacy and lead to unwanted side effects. At Ajax, we are targeting hematologic malignancies with greater precision by applying state-of-the-art computational chemistry and structural biology throughout the drug discovery and development process to create best-in-class therapies for significant unmet medical needs.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Ajax TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Cambridge, Massachusetts
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.ajaxtherapeutics.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ajax Therapeutics Announces AJX-101 Oral Presentation at EHA
    Ajax Therapeutics Announces AJX-101 Oral Presentation at EHA

    12 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/12/3292997/0/en/ajax-therapeutics-announces-oral-presentation-of-clinical-results-from-ajx-101-a-phase-i-study-of-aj1-11095-a-first-in-class-type-ii-jak2-inhibitor-at-the-european-hematology-socie.html

    GLOBENEWSWIRE
    12 May 2026
    Share Share
    Eli to buy Ajax Pharma for up to $2.3 billion in blood cancer
    Eli to buy Ajax Pharma for up to $2.3 billion in blood cancer

    27 Apr 2026

    // REUTERS

    https://www.reuters.com/legal/transactional/eli-lilly-acquire-ajax-therapeutics-up-23-billion-2026-04-27/

    REUTERS
    27 Apr 2026
    Share Share
    Ajax Therapeutics Granted U.S. FDA Orphan Drug Status
    Ajax Therapeutics Granted U.S. FDA Orphan Drug Status

    10 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/10/3203086/0/en/Ajax-Therapeutics-Receives-Orphan-Drug-Designation-from-the-U-S-FDA-for-AJ1-11095-for-the-Treatment-of-Myelofibrosis.html

    GLOBENEWSWIRE
    10 Dec 2025
    Share Share
    Ajax Therapeutics Unveils AJ1-11095, Type II JAK2 Inhibitor Data
    Ajax Therapeutics Unveils AJ1-11095, Type II JAK2 Inhibitor Data

    04 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/04/3199731/0/en/Ajax-Therapeutics-Presents-Preclinical-Data-on-Differentiated-Efficacy-Profile-of-AJ1-11095-a-First-in-Class-Type-II-JAK2-Inhibitor-at-the-American-Society-of-Hematology-Annual-Mee.html

    GLOBENEWSWIRE
    04 Dec 2025
    Share Share
    Ajax Therapeutics Names David Waller as Senior VP and Head of CMC
    Ajax Therapeutics Names David Waller as Senior VP and Head of CMC

    19 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/19/3135629/0/en/Ajax-Therapeutics-Appoints-David-Waller-PhD-as-Senior-Vice-President-and-Head-of-CMC.html

    GLOBENEWSWIRE
    19 Aug 2025
    Share Share
    Ajax Therapeutics, Schrödinger Expand JAK Research Partnership
    Ajax Therapeutics, Schrödinger Expand JAK Research Partnership

    17 Jul 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250717399124/en/Ajax-Therapeutics-and-Schrdinger-Expand-Research-Collaboration-to-Include-Additional-JAK-Target

    BUSINESSWIRE
    17 Jul 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search